Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518129 | 0.79 | PTGS1 (0.34) | KDM1AKCNH2KDM1BPTGS1PTGS2 | |
| SCHEMBL18840670 | 0.79 | PTGER4 (0.32) | — | |
| SCHEMBL25205946 | 0.79 | ABCB1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL31015995 | 0.79 | ABCB1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL25026438 | 0.73 | ACHE (0.34) | PTGS1PTGS2 | |
| SCHEMBL31053860 | 0.73 | ACHE (0.34) | PTGS1PTGS2 | |
| SCHEMBL18840671 | 0.72 | AXL (0.30) | — | |
| SCHEMBL25225834 | 0.71 | KDM1A (0.37) | KDM1AKCNH2KDM1BPTGS1PTGS2 | |
| SCHEMBL31518183 | 0.71 | ABCB1 (0.36) | KDM1APTGS1PTGS2 | |
| SCHEMBL441345 | 0.71 | KDM1A (0.43) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868052-B | Phenyl pyrrolidone formyl peptide 2 receptor agonist | 百时美施贵宝公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3981767-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981767-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3762380-B1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3762380-B1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371378-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210371378-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3762380-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-111868052-A | Phenylpyrrolidinone formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200255375-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200255375-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676431-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676431-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| WO-2019173182-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173182-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20190270704-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270704-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | KDM1A 4169/4885KCNH2 4259/4885KDM1B 4006/4885 |
| US-10676431-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | KDM1A 4169/4885KCNH2 4259/4885KDM1B 4006/4885 |
| US-20190270704-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | KDM1A 4169/4885KCNH2 4259/4885KDM1B 4006/4885 |
| US-20200255375-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | KDM1A 4169/4885KCNH2 4259/4885KDM1B 4006/4885 |
| US-20210371378-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | KDM1A 4169/4885KCNH2 4259/4885KDM1B 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.